α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease

Free Radic Biol Med. 2014 Feb:67:58-68. doi: 10.1016/j.freeradbiomed.2013.10.008. Epub 2013 Oct 19.

Abstract

Parkinson disease (PD) is a multifactorial disease resulting in preferential death of the dopaminergic neurons in the substantia nigra. Studies of PD-linked genes and toxin-induced models of PD have implicated mitochondrial dysfunction, oxidative stress, and the misfolding and aggregation of α-synuclein (α-syn) as key factors in disease initiation and progression. Many of these features of PD may be modeled in cells or animal models using the neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)). Reducing oxidative stress and nitric oxide synthase (NOS) activity has been shown to be protective in cell or animal models of MPP(+) toxicity. We have previously demonstrated that siRNA-mediated knockdown of α-syn lowers the activity of both dopamine transporter and NOS activity and protects dopaminergic neuron-like cells from MPP(+) toxicity. Here, we demonstrate that α-syn knockdown and modulators of oxidative stress/NOS activation protect cells from MPP(+)-induced toxicity via postmitochondrial mechanisms rather than by a rescue of the decrease in mitochondrial oxidative phosphorylation caused by MPP(+) exposure. We demonstrate that MPP(+) significantly decreases the synthesis of the antioxidant and obligate cofactor of NOS and TH tetrahydrobiopterin (BH4) through decreased cellular GTP/ATP levels. Furthermore, we demonstrate that RNAi knockdown of α-syn results in a nearly twofold increase in GTP cyclohydrolase I activity and a concomitant increase in basal BH4 levels. Together, these results demonstrate that both mitochondrial activity and α-syn play roles in modulating cellular BH4 levels.

Keywords: Bioenergetics; DAT; Free radicals; GTPCH; MPP(+); Parkinson disease; Tetrahydrobiopterin; α-Synuclein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenylpyridinium / toxicity
  • Adenosine Triphosphate / metabolism
  • Biopterins / analogs & derivatives*
  • Biopterins / metabolism
  • Cell Line, Tumor
  • Dopaminergic Neurons / drug effects
  • Dopaminergic Neurons / metabolism*
  • Dopaminergic Neurons / pathology
  • GTP Cyclohydrolase / genetics
  • GTP Cyclohydrolase / metabolism
  • Gene Expression Regulation
  • Guanosine Triphosphate / metabolism
  • Humans
  • Mitochondria / drug effects
  • Mitochondria / metabolism*
  • Models, Biological
  • Oxidative Phosphorylation
  • Parkinson Disease / genetics
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • alpha-Synuclein / antagonists & inhibitors
  • alpha-Synuclein / genetics*
  • alpha-Synuclein / metabolism

Substances

  • RNA, Small Interfering
  • alpha-Synuclein
  • Biopterins
  • Guanosine Triphosphate
  • Adenosine Triphosphate
  • GTP Cyclohydrolase
  • sapropterin
  • 1-Methyl-4-phenylpyridinium